A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (DENALI)
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
A Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Azenosertib is a selective and orally bioavailable inhibitor of WEE1. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage leading to mitotic catastrophe and cancer cell death.
The study consists of two parts:
Part 1: All comers, no biomarker status required (completed enrollment)
Part 2: Cyclin E1 positive protein expression required
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Project Director
- Phone Number: 858.263.4333
- Email: medicalaffairs@zentalis.com
Study Locations
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- Recruiting
- Site 2715 - Icon Cancer Centre - Chermside
-
South Brisbane, Queensland, Australia, 4101
- Recruiting
- Site 2707 - Mater Brisbane
-
-
South Australia
-
Adelaide, South Australia, Australia, 5037
- Recruiting
- Site 2709 - Cancer Research SA
-
Toorak Gardens, South Australia, Australia, 5065
- Recruiting
- Site 2702 - Burnside War Memorial Hospital - The Brian Fricker Oncology Centre
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Recruiting
- Site 2716 - Epworth Healthcare Freemasons
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- Site 2701 - Sir Charles Gairdner Hospital
-
Subiaco, Western Australia, Australia, 6008
- Recruiting
- Site 2717 - St John of God Hospital Subiaco
-
-
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgium, 1200
- Recruiting
- Site 3102 - Cliniques Universitaires Saint-Luc
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- Recruiting
- Site 3105 - UZ Leuven
-
-
-
-
-
Lyon, France, 69373
- Recruiting
- Site 3619 - Centre Léon Bérard
-
Strasbourg, France, 67200
- Recruiting
- Site 3620 - CHU de Strasbourg - Hopital de Hautepierre
-
Villejuif, France, 94800
- Recruiting
- Site 3604 - Institut Gustave Roussy
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06100
- Recruiting
- Site 3616 - Centre Antoine Lacassagne
-
-
Côte-d'Or
-
Dijon, Côte-d'Or, France, 21079
- Recruiting
- Site 3601 - Centre Georges François Leclerc
-
-
Doubs
-
Besançon, Doubs, France, 25030
- Recruiting
- Site 3613 - CHRU Besancon - Hopital Jean Minjoz
-
-
Finistere
-
Brest, Finistere, France, 29200
- Recruiting
- Site 3617 - CHU de Brest - Hôpital La Cavale Blanche
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, France, 31000
- Recruiting
- Site 3603 - Institut Claudius Regaud
-
-
Nord
-
Lille, Nord, France, 59000
- Recruiting
- Site 3602 - Centre Oscar Lambret
-
-
Paris
-
Paris, Paris, France, 75181
- Recruiting
- Site 3615 - Hôpital Cochin Port-Royal AP-HP
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, France, 44800
- Recruiting
- Site 3614 - Institut de Cancerologie de l'oust
-
-
Rhône
-
Pierre-Bénite, Rhône, France, 69310
- Recruiting
- Site 3608 - Hospices Civils de Lyon - Hôpital Lyon Sud
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Site 3303 - Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi-Via Massarenti
-
-
Campania
-
Naples, Campania, Italy, 80131
- Recruiting
- Site 3302 - Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale
-
-
Emilia-Romagna
-
Modena, Emilia-Romagna, Italy, 41124
- Recruiting
- Site 3308 - Azienda Ospedaliero Universitaria Di Modena Policlinico
-
-
Friuli Venezia Giulia
-
Aviano, Friuli Venezia Giulia, Italy, 33081
- Recruiting
- Site 3312 - Centro di Riferimento Oncologico
-
-
Lazio
-
Rome, Lazio, Italy, 168
- Recruiting
- Site 3304 - Fondazione Policlinico Universitario A Gemelli
-
-
Lombardy
-
Milan, Lombardy, Italy, 20141
- Recruiting
- Site 3305 - Istituto Europeo di Oncologia
-
Milan, Lombardy, Italy, 20159
- Recruiting
- Site 3314 - Humanitas San Pio X
-
-
Milano
-
Milan, Milano, Italy, 20132
- Recruiting
- Site 3307 - Ospedale San Raffaele S.r.l.
-
-
Veneto
-
Verona, Veneto, Italy, 37126
- Recruiting
- Site 3311 - Azienda Ospedaliera Universitaria Integrata Di Verona
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Poland, 30-348
- Recruiting
- Site 2405 - Centrum Badan Klinicznych JCI
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Poland, 15-027
- Recruiting
- Site 2419 - Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Poland, 81-519
- Recruiting
- Site 2421 - Szpitale Pomorskie Sp. z o. o.
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 935
- Recruiting
- Site 0326 - Pan American Center for Oncology Trials LLC
-
-
-
-
-
Seoul, South Korea, 03722
- Recruiting
- Site 2909 - Severance Hospital Yonsei University Health System
-
Seoul, South Korea, 06273
- Recruiting
- Site 2906 - Gangnam Severance Hospital, Yonsei University Health System
-
Seoul, South Korea, 06351
- Recruiting
- Site 2907 - Samsung Medical Center
-
Seoul, South Korea, 03080
- Recruiting
- Site 2905 - Seoul National University Hospital
-
Seoul, South Korea, 05505
- Recruiting
- Site 2904 - Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, South Korea, 10408
- Recruiting
- Site 2908 - National Cancer Center
-
-
-
-
-
Madrid, Spain, 28046
- Recruiting
- Site 3502 - Hospital Universitario La Paz
-
-
Barcelona
-
Barcelona, Barcelona, Spain, 8035
- Recruiting
- Site 3511 - Instituto de Investigacion Oncologica Vall d'Hebron
-
-
Madrid
-
Madrid, Madrid, Spain, 28027
- Recruiting
- Site 3517 - Clinica Universidad de Navarra
-
Majadahonda, Madrid, Spain, 28222
- Recruiting
- Site 3519 - Hospital Universitario Puerta de Hierro
-
-
Murcia
-
Murcia, Murcia, Spain, 30120
- Recruiting
- Site 3516 - Hospital Universitario Virgen de La Arrixaca
-
-
Valencia
-
Valencia, Valencia, Spain, 46010
- Recruiting
- Site 3501 - Hospital Clinico Universitario de Valencia
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36604
- Recruiting
- Site 0170-USA Mitchell Cancer Institute
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Site 0143 - HonorHealth
-
Tucson, Arizona, United States, 85724
- Recruiting
- Site 0102 - University of Arizona Cancer Center
-
-
California
-
La Jolla, California, United States, 92037
- Active, not recruiting
- Site 0258 - UC San Diego Moores Cancer Center
-
Santa Barbara, California, United States, 93105
- Active, not recruiting
- Site 0287 - Ridley Tree Cancer Center
-
-
Colorado
-
Lone Tree, Colorado, United States, 80218
- Recruiting
- Site 0135 - Rocky Mountain Cancer Centers
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Recruiting
- Site 0158 - Hartford HealthCare
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- Recruiting
- Site 0241 - Florida Cancer Specialist - North
-
Miami Beach, Florida, United States, 33140
- Recruiting
- Site 0173 - Mount Sinai Medical Center
-
Orlando, Florida, United States, 32803
- Recruiting
- Site 0308 - Advent Health
-
Wellington, Florida, United States, 33414
- Recruiting
- Site 0239 - Florida Cancer Specialists - East
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Site 0108 - Emory University Hospital
-
Savannah, Georgia, United States, 31404
- Active, not recruiting
- Site 0236 - Memorial Health
-
-
Illinois
-
Niles, Illinois, United States, 60714
- Active, not recruiting
- Site 0324 - Illinois Cancer Specialists
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Site 0217 - St Vincent Hospital and Health Care Centers
-
Indianapolis, Indiana, United States, 46250
- Recruiting
- Site 0284 - Community Cancer Center North
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Site 0251 - Norton Cancer Institute
-
-
Maryland
-
Rockville, Maryland, United States, 20876
- Active, not recruiting
- Site 0146 - Maryland Oncology Hematology, PA
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Recruiting
- Site 0221 - Tufts Medical Center - PPDS
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Site 0104 - Dana Farber Cancer Institute
-
Burlington, Massachusetts, United States, 01805
- Recruiting
- Site 0307 - Lahey Hospital and Medical Center
-
Springfield, Massachusetts, United States, 01199
- Recruiting
- Site 0263 - Baystate Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Site 0101 - Barbara Ann Karmanos Cancer Institute
-
Principal Investigator:
- Robert Morris
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Site 0228 - Corewell Health Medical Group West
-
-
Minnesota
-
Maplewood, Minnesota, United States, 55109
- Recruiting
- Site 0288 - Minnesota Oncology Hematology - Maplewood
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Active, not recruiting
- Site 0226 - CoxHealth
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Active, not recruiting
- Site 0317 - Nebraska Methodist Hospital
-
-
Nevada
-
Reno, Nevada, United States, 89511
- Recruiting
- Site 0213 - Center of Hope
-
-
New York
-
Manhasset, New York, United States, 11030
- Active, not recruiting
- Site 0231 - Northwell Health Cancer Institute
-
Rochester, New York, United States, 14642
- Recruiting
- Site 0126 - Wilmot Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Site 0259 - Duke Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Recruiting
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen
-
Columbus, Ohio, United States, 43219
- Recruiting
- Site 0243 - Mark H Zangmeister Cancer Center
-
Hilliard, Ohio, United States, 43026
- Recruiting
- Site 0214-Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Recruiting
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Site 0232 - University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Site 0178 - Thomas Jefferson University
-
Wynnewood, Pennsylvania, United States, 19096
- Active, not recruiting
- Site 0277 - Alliance Cancer Specialist, PC
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Recruiting
- Site 0132 - Avera Cancer Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Site 0103 - University of Texas MD Anderson Cancer Center
-
Tyler, Texas, United States, 75702
- Recruiting
- Site 0203 - Texas Oncology
-
-
Virginia
-
Chesapeake, Virginia, United States, 23320
- Recruiting
- Site 0295 - Virginia Oncology Associates
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Site 0322 - Inova Schar Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Age ≥18 years
-
High-grade serous ovarian, fallopian tube or primary peritoneal cancer
-
Tumor testing (archival acceptable) confirms a positive Cyclin E1 protein status result determined by IHC using the Sponsor's investigational clinical trial assay
-
Prior therapy:
- Subjects must have platinum-resistant disease
- Part 2c: Subjects with PROC may have 1 to 4 prior lines or regimens. Prior treatment in this cohort includes a weekly taxane regimen, either as single agent or in combination, per protocol
- Prior bevacizumab treatment is required, if eligible per standard of care
- Prior PARP inhibitor treatment is required if BRCA 1/2 mutation or HRD, if eligible per standard of care
- Prior mirvetuximab treatment is required, if eligible per standard of care
-
Measurable disease per RECIST Version 1.1.
-
Adequate hematologic and organ function, as defined in protocol
-
ECOG 0-1
Exclusion Criteria:
-
Primary platinum-refractory disease
-
Subjects with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, low-grade, borderline, or other ovarian tumors
-
Any of the following treatment interventions within the specified time frame prior to C1D1:
- Major surgery within 28 days
- Hospitalization within 14 days
- Any chemotherapy or targeted tumor therapy within 21 days or 5 half-lives (whichever is shorter);
- Radiation therapy within 21 days;
- Autologous or allogeneic stem cell transplant within 3 months.
- Current use of any other investigational drug therapy <28 days or 5 half-lives (whichever is shorter).
- Inability to discontinue treatment prescription or non-prescription drugs, or to discontinue consumption of food and herbal supplements that are strong or moderate CYP3A inhibitors and inducers or P-gp inhibitors at least 14 days prior to C1D1.
-
Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.
-
A serious illness or medical condition(s) including, but not limited to:
- Clinically or radiographically unstable brain metastases or leptomeningeal disease that requires immediate treatment. Subjects with asymptomatic brain metastases are eligible.
- Myocardial impairment resulting in heart failure (NYHA Class II-IV)
- Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or may interfere with interpretation of study results
- Acute kidney injury requiring intervention or intravenous fluid in the last 14 days or presence of indwelling urinary catheter or percutaneous nephrostomy.
- Significant gastrointestinal abnormalities, including an inability to take oral medication, requirement for intravenous alimentation, active peptic ulcer, chronic diarrhea or vomiting considered to be clinically significant in the judgment of the Investigator, or prior surgical procedures affecting absorption.
- Active, uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal, or antiviral) must have completed such treatment and the infection must be considered controlled/resolved (and afebrile) by the Investigator for at least 7 days before C1D1
- Any evidence of bowel obstruction as determined by air/fluid levels on computed tomography (CT scan, recent hospitalization for small bowel obstruction within 3 months prior to C1D1, or recurrent paracentesis or thoracentesis within 6 weeks prior to C1D1.
-
Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding Grade ≤2 neuropathy, alopecia, or skin pigmentation).
-
Pregnant or lactating female subject or female subject of childbearing potential who has a positive serum pregnancy test within 14 days prior to C1D1.
-
History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free. Exceptions include appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, or other malignancies with an expected curative outcome.
-
Subjects who are known to be immunocompromised or HIV-positive on highly active anti-retroviral therapy.
-
Subjects with known active hepatitis B or hepatitis C infection.
-
Individuals who are judged by the Investigator to be unsuitable as study subjects.
-
Subjects who had prior wide-field radiotherapy affecting ≥ 20% of the bone marrow.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1a/1b (Completed Enrollment)
Azenosertib 400mg administered once daily on a 5 days on, 2 days off intermittent schedule. |
Azenosertib (ZN-c3) will be administered orally.
Other Names:
|
|
Experimental: Part 2a: Arm 1 (Completed Enrollment)
Azenosertib 400mg administered once daily on a 5 days on, 2 days off intermittent schedule |
Azenosertib (ZN-c3) will be administered orally.
Other Names:
|
|
Experimental: Part 2a: Arm 2 (Completed Enrollment)
Azenosertib 300mg administered once daily on a 5 days on, 2 days off intermittent schedule |
Azenosertib (ZN-c3) will be administered orally.
Other Names:
|
|
Experimental: Part 2b (Completed Enrollment)
Azenosertib 400mg administered once daily on a 5 days on, 2 days off intermittent schedule |
Azenosertib (ZN-c3) will be administered orally.
Other Names:
|
|
Experimental: Part 2c (Enrolling)
Azenosertib 400mg administered once daily on a 5 days on, 2 days off intermittent schedule |
Azenosertib (ZN-c3) will be administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR) defined by RECIST v1.1 [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria. |
Up to approximately 12 months from the enrollment of the last subject
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects experiencing treatment emergent adverse events (TEAEs) [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
Up to approximately 12 months from the enrollment of the last subject
|
|
|
Duration of response (DOR) defined by RECIST v1.1 [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
Time from the date of first documented response (CR or PR that is subsequently confirmed per RECIST v1.1) until the date of progressive disease (PD) or death. |
Up to approximately 12 months from the enrollment of the last subject
|
|
Progression free survival (PFS) defined by RECIST v1.1 [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
Time from the date of first dose until the date of PD or death. |
Up to approximately 12 months from the enrollment of the last subject
|
|
Clinical Benefit Rate (CBR) defined by RECIST v1.1 [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
The percentage of participants who have at least 1 confirmed response of CR or PR, or stable disease for at least 16 weeks before any evidence of progression. |
Up to approximately 12 months from the enrollment of the last subject
|
|
CA-125 response by GCIG criteria [Part 2]
Time Frame: Up to approximately 12 months from the enrollment of the last subject
|
The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. |
Up to approximately 12 months from the enrollment of the last subject
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Ovarian Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- ZN-c3-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.